Key result
The G1021A mutation in the RYR1 gene was not found in any of the 279 North American patients tested, regardless of malignant hyperthermia susceptibility.
Why the study?
What is the prevalence of the RYR1 G1021A mutation in North American patients evaluated for malignant hyperthermia?
Case-Control (n=279)
What is the prevalence of the RYR1 G1021A mutation in North American patients evaluated for malignant hyperthermia?
The RYR1 G1021A mutation, which is frequent in European populations, is absent in this North American cohort, highlighting the geographical variability of malignant hyperthermia genetics.
Answers are grounded in this paper and cite their sources.
G1021A is absent in North American MH patients; leaves open ancestry-specific RYR1 testing panels.
Anesthesia-induced malignant hyperthermia (MH) is a rare inherited disorder of skeletal muscle. Several mutations in the ryanodine receptor (RYR1) have been found to be causative of MH. The G1021A mutation in the RYR1 is one of the most frequently occurring mutations in European populations. MH normal (165) and MH susceptible (114) North American patients were screened for the presence of the G1021A mutation. This mutation was not found in any of the patients tested. These studies support the absence of this mutation in the normal population. Furthermore, these findings emphasize the importance of viewing the distribution of MH mutations as variable gene pools with frequencies dependent on the geographical location of the population examined.
No takes yet. Share an insight, caveat, or question.
Stewart et al. (1998) conducted a case-control in Malignant hyperthermia (n=279). Malignant hyperthermia susceptibility vs. Malignant hyperthermia normal was evaluated on Presence of the G1021A mutation. The G1021A mutation in the RYR1 gene was not found in any of the 279 North American patients tested, regardless of malignant hyperthermia susceptibility.
Synapse has enriched 10 related papers. Consider them for comparative context: